EUVIMEDEUVIMED entdecken
Open Access

Forced vital capacity in pulmonary exacerbations of cystic fibrosis

Oliver J McElvaney, Sonya L Heltshe, Don B Sanders, Natalie E West, Kathleen J Ramos, Barbra Fogarty, Patrick A Flume, Christopher H Goss, STOP2 Investigators

Journal of Cystic Fibrosis · 2026-07

DOI: 10.1016/j.jcf.2026.07.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2026-07. Verfasst von Oliver J McElvaney und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA; Division of Pulmonary,…. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, University of Washington.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Forced expiratory volume in one second (FEV₁) is routinely used to assess pulmonary exacerbations (PEx) in cystic fibrosis (CF) but underrepresents air trapping and small airways dysfunction. Forced vital capacity (FVC) may better capture these processes, yet its behavior, clinical relevance, and utility as a trial endpoint remain uncertain. METHODS: We performed a secondary analysis of STOP2, a multicenter randomized trial of antimicrobial duration in adults with CF pulmonary exacerbations (PEx). Changes in percent-predicted FVC (ppFVC) and FEV₁ (ppFEV₁) were assessed relative to pre-PEx baseline. Clinical characteristics associated with large ppFVC decline were evaluated using adjusted analyses. Propensity score matching was used to compare recovery, residual deficit, and symptom response between groups with large versus modest ppFVC decline. Associations with time-to-next-exacerbation (TTNE) were assessed using survival analyses. Variability, responsiveness, and projected clinical trial sample sizes were compared between ppFVC- and ppFEV₁-based endpoints. RESULTS: Among 760 participants, ppFVC responses were heterogeneous. Larger absolute declines were associated with higher baseline FVC and elevated C-reactive protein (CRP), while larger relative declines were associated with CRP alone. Participants with large initial ppFVC deficits showed greater absolute recovery but larger residual deficits, shorter TTNE, and higher future exacerbation risk. A one-standard-deviation worse residual ppFEV₁ deficit was associated with increased re-exacerbation risk, whereas residual ppFVC deficit was weaker and not independently prognostic. Absolute recovery in either measure was not associated with TTNE. Compared with ppFEV₁, ppFVC demonstrated similar or greater variability, resulting in larger estimated sample sizes for clinical trials. CONCLUSIONS: Distinct FVC response patterns occur during CF PEx but do not provide independent prognostic information beyond FEV₁. Use of ppFVC as a primary endpoint would require larger sample sizes without clear advantage.

Schlagwörter

Stichwörter der Autor:innen

Clinical trialCystic fibrosisEndpointsExacerbationFVCForced vital capacitySpirometry

Autor:innen und Institutionen

  • Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA; Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington, Seattle,…
  • Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA.
  • Department of Pediatrics, Indiana University, Indianapolis, IN, USA.
  • Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
  • Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA.
  • Department of Pediatrics, Medical University of South Carolina, Charleston, SC, USA; Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • University of Washington
  • National Institutes of Health
  • National Center for Advancing Translational Sciences
  • Cystic Fibrosis Foundation

Zitieren

APA

McElvaney, O. J., Heltshe, S. L., Sanders, D. B., West, N. E., Ramos, K. J., Fogarty, B., Flume, P. A., Goss, C. H., & STOP2 Investigators (2026). Forced vital capacity in pulmonary exacerbations of cystic fibrosis. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2026.07.010

Vancouver

McElvaney OJ, Heltshe SL, Sanders DB, West NE, Ramos KJ, Fogarty B, et al. Forced vital capacity in pulmonary exacerbations of cystic fibrosis. Journal of Cystic Fibrosis. 2026. doi:10.1016/j.jcf.2026.07.010

BibTeX
@article{McElvaney2026,
  author = {McElvaney, Oliver J and Heltshe, Sonya L and Sanders, Don B and West, Natalie E and Ramos, Kathleen J and Fogarty, Barbra and Flume, Patrick A and Goss, Christopher H and STOP2 Investigators, STOP2 Investigators},
  title = {Forced vital capacity in pulmonary exacerbations of cystic fibrosis},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  doi = {10.1016/j.jcf.2026.07.010}
}
Kostenlos starten →